NCT01631487View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Healthy
Interventions
DRUG

JNJ-39439335 10 mg

Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.

DRUG

JNJ-39439335 25 mg

Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.

DRUG

JNJ-39439335 50 mg

Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.

DRUG

Placebo

Multiple (once daily for 21 days) oral doses of matching placebo.

Trial Locations (1)

Unknown

Cypress

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01631487 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants | Biotech Hunter | Biotech Hunter